To determine the therapeutic potential of SLC39A10 inhibition in gastric cancer, we stably knocked down SLC39A10 in MKN45 cells via a lentivirus system and used SLC39A10-knockdown MKN45 cells and control cells to establish a xenograft tumor model. This evidence concerns the gene SLC39A10 and neoplasm.